Phathom Pharmaceuticals에 대한 매도 수량은 투자자에게 Phathom Pharmaceuticals의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Phathom Pharmaceuticals (NASDAQ:PHAT) 주식, 공매도 수량 보고

Phathom Pharmaceuticals

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Phathom Pharmaceuticals, Inc. - Common Stock

Phathom Pharmaceuticals Inc

Baird analyst Andrew Wittmann maintains AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) with a Outperform and lowers the price target from $125 to $117.

News

Price Target

Analyst Ratings

Baird Maintains Outperform on AECOM, Lowers Price Target to $117

WIIM

CNH Industrial shares are trading lower after the company issued FY25 adjusted EPS results below estimates.

Cybersecurity provider Check Point Software Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHKP#NASDAQ">CHKP</a>) shares are trading higher premarket on Tuesday. The company disclosed enhanced capabilities for its Infinity Platform, which aim to accelerate zero-trust adoption, bolster threat prevention, reduce complexity,<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43455281/check-point-announces-new-ai-powered-innovations-to-bolster-unified-security-management-for-the-in" rel="noreferrer noopener"> and streamline security operations</a>.
By integrating AI and identity awareness, administrators can enforce more precise security policies, granting access only to authorized users.
Centralized visibility and policy analysis across environments help security teams uphold compliance and maintain strong security practices.
Nataly Kremer, Chief Product Officer at Check Point, said, &#8220;We are pleased to introduce several new AI-powered Innovations that cut down complexity and strengthen the Unified Security Management capabilities of the Infinity Platform.&#8221;
&#8221;Our customers will experience enhanced threat prevention, while finding it very easy to collaborate with third-party products.&#8221;
Last month, the company reported fiscal fourth-quarter revenue growth of 6% year-on-year to $703.70 million, topping the&nbsp;analyst <a target="_blank" href="https://www.benzinga.com/news/earnings/25/01/43347093/check-point-q4-earnings-revenue-and-eps-beat-security-subscriptions-surge-expands-cybersecurity-offerings-despite-margin-pressure" rel="noreferrer noopener">consensus estimate of $698.82 million</a>.&nbsp;
The American Israeli enterprise security solution&nbsp;provider&#8217;s&nbsp;adjusted EPS of $2.70 beat the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate of $2.66</a>.
Investors can gain exposure to the stock via Amplify ETF Trust Amplify BlueStar Israel Technology ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITEQ#NYSE">ITEQ</a>) and VanEck Israel ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ISRA#NYSE">ISRA</a>).
Price Action: CHKP shares are up 0.67% at $215.30 premarket at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/43455908" target="_blank" rel="noreferrer noopener">Dogecoin Regains Momentum After &#8216;Black Sunday&#8217; Rout—Here&#8217;s What Indicators Signal About The Memecoin&#8217;s Next Moves</a></li>
</ul>
Image via Shutterstock.

Equities

Large Cap

CHKP

ISRA

ITEQ

Check Point Boosts Threat Prevention with Upgraded Infinity Platform

Barclays analyst Richard Hightower maintains NNN REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NNN#NYSE">NNN</a>) with a Overweight and lowers the price target from $48 to $46.

Barclays Maintains Overweight on NNN REIT, Lowers Price Target to $46

Vodafone Group shares are trading lower after the company reported Q3 financial results.

ZENA

ZenaTech Inks LOI To Acquire A Fifth Land Survey Company In Southeast Florida

REGN

Regeneron shares are trading higher after the company reported better-than-expected Q4 financial results. The company also approved a $3 billion share repurchase program and initiated a quarterly cash dividend.

Baird analyst Catherine Ramsey maintains Twist Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>) with a Outperform and raises the price target from $48 to $54.

TWST

Baird Maintains Outperform on Twist Bioscience, Raises Price Target to $54

Guidance

ATI Sees Q1 2025 Adj. EPS $0.55-$0.61 Vs $0.48 Estimate; Sees FY25 Adj. EPS $2.80-$3.00 Vs $2.88 Estimate

ATI Sees Q1 2025 Adj. EBITDA $170M-$180M; Sees FY25 Adj. EBITDA $800M-$840M

Jefferies analyst Omar Nokta maintains Flex LNG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLNG#NYSE">FLNG</a>) with a Hold and maintains $23 price target.

FLNG

Jefferies Maintains Hold on Flex LNG, Maintains $23 Price Target

RACE

Ferrari shares are trading higher after the company reported better-than-expected Q4 financial results.

D. Boral Capital analyst Jason Kolbert maintains CollPlant Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLGN#NASDAQ">CLGN</a>) with a Buy and maintains $14 price target.

CLGN

D. Boral Capital Maintains Buy on CollPlant Biotechnologies, Maintains $14 Price Target

The Company expects full year 2025 free cash flow conversion of 90% or greater on adjusted net income.

HUBB

Hubbell Expects FY25 Adj. EPS Of $17.35 - $17.85 (Est $17.70); Anticipates Total Sales Growth And Organic Sales Growth Of 4% - 5%

Lancaster Colony (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LANC#NASDAQ">LANC</a>) reported quarterly earnings of $1.78 per share which missed the analyst consensus estimate of $1.93 by 7.77 percent. This is a 7.77 percent decrease over earnings of $1.93 per share from the same period last year. The company reported quarterly sales of $509.30 million which beat the analyst consensus estimate of $495.47 million by 2.79 percent. This is a 4.81 percent increase over sales of $485.92 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

LANC

Lancaster Colony Q2 EPS $1.78 Misses $1.93 Estimate, Sales $509.30M Beat $495.47M Estimate

Rosenblatt analyst Steve Frankel maintains Harmonic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLIT#NASDAQ">HLIT</a>) with a Buy and maintains $16 price target.

HLIT

Rosenblatt Maintains Buy on Harmonic, Maintains $16 Price Target

Biotech

General

PYXS

Pyxis Oncology Initiates Phase 1/2 Combination Trial Of PYX-201 With KEYTRUDA

Northland Capital Markets analyst Mike Grondahl maintains Applied Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) with a Outperform and raises the price target from $12 to $20.

APLD

Northland Capital Markets Maintains Outperform on Applied Digital, Raises Price Target to $20

Shares of Applied Materials Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) have risen by 9.11% this year despite last week&#8217;s declines in semiconductor-linked companies fueled by the emergence of <a href="https://www.benzinga.com/25/01/43379565/deepseeks-ai-model-shook-wall-street-but-a-new-report-says-chinese-state-accounts-helped-fan-the-flames">DeepSeek&#8217;s V3</a> chatbot. Here&#8217;s what the company&#8217;s technical and fundamental metrics reveal.
What Happened: Applied Materials is a U.S. company that provides equipment, services, and software for manufacturing semiconductors, displays, and solar products to chipmakers.
While most semiconductor-linked and chipmaker stocks took a hit after DeepSeek&#8217;s chatbot emerged as the top application on the Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) app store, AMAT has risen by 2.86% over the last five trading sessions.
However, the technical analysis of its simple daily moving averages signals a short-term downtrend with a potential for a slight rebound.
AMAT shares closed Friday at $178.80, significantly lower than its 200-day simple moving average of $197.50, and 20-day average at $180.68. Also, lower than its eight-day average of $178.64, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. However, the stock was above its 50-day average of $174.63, which acted as support, and indicated some signs of stabilization.
The momentum indicators for the stock were mixed. The relative strength index of 50.47 shows that the stock is in the neutral zone. whereas the positive MACD (moving average convergence/divergence) indicator of 1.46 suggests potential for upward momentum in the near term.
<figure class="wp-block-image size-large"><a href="https://pro.benzinga.com/dashboard"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04070742/AMAT-tech-Chart-1024x576.png" alt="" class="wp-image-764620" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04070742/AMAT-tech-Chart-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04070742/AMAT-tech-Chart-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04070742/AMAT-tech-Chart-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04070742/AMAT-tech-Chart-1536x864.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04070742/AMAT-tech-Chart.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
See Also: <a href="https://www.benzinga.com/general/market-summary/25/02/43454291/winner-winner-chicken-dinner-tyson-foods-q1-beat-showcases-improved-execution-in-poultry-says-ceo" target="_blank" rel="noreferrer noopener">Winner Winner, Chicken Dinner: Tyson Foods Q1 Beat Showcases ‘Improved Execution&#8217; In Poultry, Says CEO</a>
Why It Matters: The company will report its first-quarter earnings on Feb. 13 after market close. Applied Materials has continuously exceeded its earnings <a href="https://www.benzinga.com/quote/AMAT/earnings">expectations</a> over the last 10 quarters, as tracked by Benzinga. 
Benzinga&#8217;s consensus expects it to deliver earnings of $2.32 per share on the revenue of $7.19 billion in the first quarter.
Despite a mixed technical picture for the stock, the 27 analysts <a href="https://www.benzinga.com/quote/AMAT/analyst-ratings">tracked by Benzinga</a> remain positive on the company with a &#8216;buy&#8217; rating and consensus price target of $207.7.
The targets range between $140 to $280, with the three recent issuances by Susquehanna, Keybanc, and Barclays indicating an average of $196.67 apiece, which implies a 9.86% upside.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/AMAT/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="378" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04070647/AMAT-ANR-1024x378.png" alt="" class="wp-image-764619" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04070647/AMAT-ANR-1024x378.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04070647/AMAT-ANR-300x111.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04070647/AMAT-ANR-768x284.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04070647/AMAT-ANR.png 1066w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Price Action: Applied Materials was up 0.22% in premarket on Tuesday, whereas the exchange-traded fund tracking Nasdaq 100, Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) was up 0.13% at $518.76. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/02/43456454/bill-gates-says-nvidias-jensen-huang-could-be-wrong-about-quantum-computing-qubt-rgti-ionq-react-in-tuesday-premarket">Bill Gates Says Nvidia&#8217;s Jensen Huang &#8216;Could Be Wrong&#8217; About Quantum Computing: QUBT, RGTI, IONQ React In Tuesday Premarket</a></li>
</ul>
Photo courtesy: Shutterstock

Technicals

Markets

Trading Ideas

AAPL

AMAT

Chip Equipment Maker Applied Materials Stock Is Up Over 9% YTD Even As Charts Point To Bearish Patterns: Here's What Investors Should Look At

ADM Expects FY25 Adjusted EPS Of $4.00 - $4.75 (Est $4.67), Reflecting Weaker Market Fundamentals And On-going Biofuel And Trade Policy Uncertainty

Catalyst Watch: November jobs, OPEC+ meeting, Marvell, Salesforce earnings

Salesforce, Marvell Technology, And Kroger Report As Earnings Season Slowing To A Crawl

Phathom Pharmaceuticals (PHAT) announced it has submitted a Citizen Petition, CP, with the U.S. Food and Drug Administration, FDA. The petition for...

Phathom Pharmaceuticals submits Citizen Petition to FDA

Needham analyst Joseph Stringer maintained a Buy rating on Phathom Pharmaceuticals (PHAT – Research Report) today and set a price target of $28.00....

Phathom Pharmaceuticals: Undervalued Opportunity with Strategic Moves for Extended Exclusivity

Phathom Pharmaceuticals: The Large Drop Is, Well, Unfathomable

In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on Phathom Pharmaceuticals (PHAT – Research Report), with...

Phathom Pharmaceuticals: Securing Long-term Exclusivity for Growth Potential

In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on Phathom Pharmaceuticals (PHAT – Research Report). The ...

Craig-Hallum Remains a Buy on Phathom Pharmaceuticals (PHAT)

Investing in biotechnology stocks offers a unique opportunity for individuals looking to gain exposure to one of the most dynamic and innovative sectors of the market.

Top Biotech Short Squeeze Stocks

Optimistic Outlook on Phathom Pharmaceuticals: Buy Rating Amid Market Undervaluation

Needham's top stocks for 2025: AX, CYBR, CART and more

ABBV

ACVA

ALGM

AMZN

ATSG

AXSM

CAKE

CART

CELH

CHWY

CRDO

CRVO

CSGP

CTLT

CYBR

DAVA

DECK

DLTR

DOCU

FIVE

FLYE

GALT

GAUZ

GTLB

HIMS

HOOD

IMPP

JANX

KIRK

KLAC

LITE

LQDA

LULU

MKFG

MRVL

MTEM

NAMI

NNDM

NVDA

OKTA

ONTO

PHAT

PSTG

PSTX

QCOM

RAPP

RILY

ROKU

SAVA

SCWX

SGHC

SHAK

SLAB

SNPS

SOFI

TENB

TSCO

TSHA

ULTA

VALE

VRNT

Press Releases

Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT)

Health Care

Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting

Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024

Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates

Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets

Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference

Comments

Phathom Pharmaceuticals

매도 수량

Phathom Pharmaceuticals (NASDAQ:PHAT) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌